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Abstract
We and others have previously demonstrated that the acute release of progenitor cells in response to chemotherapy
actually reduces the efficacy of the chemotherapy. Here, we take these data further and investigate the clinical rele-
vance of circulating endothelial (progenitor) cells (CE(P)Cs) and modulatory cytokines in patients after chemotherapy
with relation to progression-free and overall survival (PFS/OS). Patients treated with various chemotherapeutics were
included. Blood sampling was performed at baseline, 4 hours, and 7 and 21 days after chemotherapy. The mono-
nuclear cell fraction was analyzed for CE(P)C by FACS analysis. Plasma was analyzed for cytokines by ELISA or
Luminex technique. CE(P)Cs were correlated with response and PFS/OS using Cox proportional hazard regression
analysis. We measured CE(P)Cs and cytokines in 71 patients. Only patients treated with paclitaxel showed an im-
mediate increase in endothelial progenitor cell 4 hours after start of treatment. These immediate changes did not
correlate with response or survival. After 7 and 21 days of chemotherapy, a large and consistent increase in CE(P)C
was found (P< .01), independent of the type of chemotherapy. Changes in CE(P)C levels at day 7 correlated with an
increase in tumor volume after three cycles of chemotherapy and predicted PFS/OS, regardless of the tumor type
or chemotherapy. These findings indicate that the late release of CE(P)C is a common phenomenon after chemo-
therapeutic treatment. The correlation with a clinical response and survival provides further support for the biologic
relevance of these cells in patients’ prognosis and stresses their possible use as a therapeutic target.
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Introduction
In the past years, the concept of angiogenesis has evolved from a sim-
ple model of the formation of new blood vessels from the preexisting
vasculature into a multifaceted process in which, beyond local acti-
vation and division of endothelial cells, bone marrow–derived endo-
thelial progenitor cells (EPCs) contribute to neovascularization. It
was postulated that EPCs are mobilized from the bone marrow into
the circulation and subsequently home to sites of tumor neovascular-
ization, where they differentiate into endothelial cells and contribute
to angiogenesis [1–3]. However, controversy exists on the relative
contribution of the EPC to the tumor vasculature, varying from less
than 1% up to more than 50% [1,4–12]. Whereas the bone marrow
does not seem to play an important role in supporting unperturbed
tumor growth, an immediate and very effective release of progenitor
cells is seen when the tumor or system is provoked by stress signals
such as surgery or chemotherapy [14–16]. Recently, it was shown that
EPCs egress the bone marrow and home to the tumor immediately
after certain types of chemotherapy, predominantly paclitaxel. EPCs
are mobilized from the bone marrow and home to sites of tumor
neovascularization in response to various cytokines, such as stroma
Abbreviations: CEC, circulating endothelial cell; EPC, endothelial progenitor cell; MNC,
mononuclear cell; OS, overall survival; PD, progressive disease; PFS, progression-free sur-
vival; PR, partial remission; SD, stable disease
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cell–derived factor-1 α (SDF-1α), matrix metalloproteinase-9, vascular
endothelial growth factor (VEGF), placental growth factor (PlGF), and
granulocyte colony-stimulating factor (G-CSF) [1,2,13,15,18,21,35–
39]. SDF-1α belongs to the chemokine family and binds to the
CXCR-4 receptor. SDF-1α plays a key role in both the release and
the homing process of EPCs; high concentrations in the bone marrow
holds the stem cells in their niche. Various factors, including G-CSF,
VEGF, and PlGF, deplete SDF-1α in the bone morrow and, sub-
sequently, permit the egress of stem cells into the circulation. In turn,
circulating stem cells, which express the SDF-1α receptor CXCR4,
home toward SDF-1α. Within the tumor, the concentration of
SDF-1α is increased in response to VEGF [38]. The acute mobiliza-
tion after paclitaxel could be effectively inhibited by antibodies against
the VEGF and CXCR-4 pathway, leading to enhanced antitumor ef-
ficacy particularly of these chemotherapeutics [15]. Besides EPC, ma-
ture circulating endothelial cells (CECs) are increased in the blood of
cancer patients and correlate with angiogenesis and tumor volume
[17–29]. CECs appear in the peripheral blood of cancer patients either
because of release from the bone marrow, similar to EPC, or because of
shedding from activated or damaged (tumor) vessels. Viable CECs
may therefore reflect angiogenic activity, whereas apoptotic CECs
may act as a surrogate marker for vascular damage [17,30]. These find-
ings have provided new insight into the mechanism of tumor re-
growth, resistance to chemotherapy, early recurrence, and metastasis
formation during or after chemotherapy.
However, little is known of EPC and CEC kinetics during chemo-
therapy in humans. The bone marrow depression and recovery, gen-
erally seen after chemotherapy, might influence the temporal changes
in CEC and EPC and might be of importance when considering these
cells as potential markers for therapy. Here we investigated the tem-
poral changes in EPC and CEC and modulatory cytokines during
the first cycle of chemotherapy. We show that the increase in EPC
and CEC levels 21 days after start chemotherapy by far exceeds the
change immediately after chemotherapy. Furthermore, we provide
evidence that the magnitude of the increase in CEC and EPC levels
after chemotherapy correlates with response and survival. These find-
ings suggest that continuous suppression of EPC and CEC is impor-
tant for optimizing treatment efficacy.
Patients and Methods
Characterization of Study Patients and Protocol
Blood samples were prospectively collected from cancer patients
receiving maximum tolerated dose chemotherapy in a thrice weekly
schedule either as (neo)adjuvant chemotherapy or as chemotherapy
for metastatic disease. All patients with previous chemotherapy or
surgery within 4 weeks were excluded. Patients were recruited be-
tween July 2006 and October 2008 in UMC Utrecht Cancer Center;
follow-up ended on March 2009. The study was approved by the in-
stitutional ethics committee, and written informed consent was ob-
tained from all patients. Blood sampling was performed before the
first cycle of chemotherapy, 4 hours and 7 days thereafter and imme-
diately before the second cycle (day 21). Response evaluation was per-
formed after the third cycle of chemotherapy according to RECIST
criteria. Progression-free survival (PFS) was defined as time from start
chemotherapy to date of tumor progression according to RECIST.
Time from start chemotherapy to date of patients’ death was deter-
mined as overall survival (OS).
Plasma and Mononuclear Cell Isolation
EDTA plasma and mononuclear cells (MNCs) were collected using
an EDTA vacutainer (Becton Dickinson, Mountain View, CA) and a
cell preparation tube with sodium citrate (Becton Dickinson). Isolation
of the MNCs occurred by centrifuging the cell preparation tubes at
1600g at room temperature for 30 minutes. The MNCs were washed
once in RPMI and stored in 10% DMSO at −80°C until analysis.
EDTA tubes were centrifuged at 800g at 4°C for 15 minutes. Plasma
was stored immediately at −80°C.
Enumeration of CEC/CEPs by Flow Cytometry
CECs and EPCs were quantified by flow cytometry analysis ac-
cording to the protocol described by Shaked et al. [15]. Briefly, a
four-color FACS analysis (FACSCalibur; BD Biosciences, Franklin
Lakes, NJ) was performed on MNCs. Mature CECs were defined
as negative for hematopoietic marker CD45 (PerCP; BD Biosciences)
and positive for endothelial cell markers CD31 (fluorescein isothio-
cyanate; BD Biosciences) and CD146 (phycoerythrin; BD Bios-
ciences). EPCs were defined as negative for CD45 and positive for
CD31 and stem cell marker CD133 (allophycocyanin; BD Bios-
ciences). MNCs were stained according to standard methods [31,32].
Corresponding isotypes were used to correct for nonspecific binding.
MNCs from healthy volunteers, human microvascular endothelial
cells, and NT2 cells were used as positive controls. Gating and analysis
were performed following standard protocols [31,32]. A minimum of
400,000 events was counted, and CECs and EPCs were calculated to
number of cells per milliliter of blood using the mononuclear cell count
of the original sample. CEC/EPC levels were normalized to the base-
line values and expressed as percent change to minimize variability due
to a large variation in baseline CEC and EPC levels.
Cytokine Analysis
Plasma G-CSF and SDF-1α were determined by commercially avail-
able ELISAs (Quantikine; R&DSystems, Abingdon, UK). VEGF, PlGF,
and FGF were quantified by commercially available Luminex (R&D
Systems) following the manufacturer’s instructions.
Statistical Methodology
Statistical comparisons were performed using the (paired) t test and
Pearson correlation when data were normally distributed and non-
parametric analysis of Mann-Whitney and Wilcoxon signed rank test
otherwise. To associate changes in CEC and EPC levels (separately or
combined) for PFS and OS, variables were both tested as continuous
variables applying univariable Cox regression proportional hazard
(PH) analysis and dichotomized for Kaplan-Meier estimation. Differ-
ences were evaluated using the log-rank test, and hazard ratios were ob-
tained. All results were analyzed using SPSS 15.0 (SPSS, Inc, Chicago,
IL) and GraphPad Prism version 4.00 (GraphPad Software, San Diego,
CA). Error bars shown are SEM. P < 0.05 (two-sided) was consid-
ered significant.
Results
Patient Characteristics
Eighty-two patients with different malignancies, treated with var-
ious forms of chemotherapy, were enrolled in this study. Eleven pa-
tients did not finish the blood sampling owing to early withdrawal of
informed consent, mainly because of the requirement of a second intra-
venous access. Seventy-one patients were evaluable for the analysis of
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changes in CEC, EPC, and growth factors after chemotherapy. Nine
patients were treated with adjuvant chemotherapy and, by definition,
not evaluable for response to treatment; nine more patients were not
evaluable according to RECIST and were therefore excluded. Ulti-
mately, 53 patients were evaluable to associate changes in CEC/EPC
levels after chemotherapy with response to treatment. For 40 patients,
the predictive value of the changes in CEC/EPC levels for PFS and OS
was analyzed, as 13 patients receiving neoadjuvant chemotherapy were
excluded from this analysis. Table 1 summarizes the demographics,
follow-up, and tumor types of all patients.
Changes in CECs and EPCs during the First Cycle
of Chemotherapy
Overall, an increase was seen in CECs and EPCs after the first cycle
of chemotherapy. Almost half of the patients (42%) already showed
a moderate increase in CEC 4 hours after chemotherapy (mean,
176%; 95% confidence interval [CI], 76%-277%; NS). Regarding
EPCs, as shown before [15], only patients treated with taxane-based
chemotherapy showed an immediate increase of EPC (mean, 181%;
95% CI, 50%-311%; P < .05) compared with a mean decrease of
85% (95% CI, 48%-123%) in other chemotherapy groups (signifi-
cant difference, P < .01).1 After 7 and 21 days, the increase of CECs
and EPCs was substantially higher and consistently present after all
types of chemotherapy. At day 7, CEC levels were increased to 192%
(95% CI, 133%-252%; P < .01), and EPC levels were slightly in-
creased to 114% (95% CI, 78%-151%; NS). On day 21, CEC and
EPC levels were further increased to 418% (95% CI, 203%-632%;
P < .01) and 304% (95% CI, 176%-1431%; P < .01; Figure 1,
A and B), respectively.
This increase in CECs and EPCs was also seen in patients receiving
adjuvant chemotherapy, although to a lesser extent and not reaching
significance. At 7 and 21 days after chemotherapy, a mean increase in
CECs of 250% (95% CI, 8%-486%; P = .16) and 275% (95% CI,
21%-987%; P = .08), respectively, was seen. EPCs were slightly de-
creased after 7 days (mean, 63%; 95% CI, 8%-128%; P = .2) but
increased after 21 days to 231% (95% CI, 61%-1243%; P = .18).
The levels of CECs and EPCs at days 7 and 21 in patients treated with
adjuvant chemotherapy did not significantly differ from changes seen
in patient with advanced disease (P = .8; Figure 1, E and F ).
Cytokine Changes during the First Cycle of Chemotherapy
To determine the possible causes of the increase in CECs and
EPCs, various cytokines were quantified in the patients’ plasma. Four
hours after chemotherapy, a significant increase in plasma SDF-1α
was found in all patients treated with taxane-based chemotherapy
(n = 6; mean, 135%; 95% CI, 108%-212%; P = .01); in all other
patients, levels remained stable. In all patients, 4 hours after chemo-
therapy, a significant increase in PlGF levels (P < .05) was observed.
In contrast, VEGF and FGF levels showed an immediate decrease
within 4 hours after chemotherapy (P < .05). G-CSF levels remained
stable. Seven days after chemotherapy, there was a significant increase
in SDF-1α (P < .01) and G-CSF (P < .001; Figure 1, C and D).
These increases were seen after all chemotherapeutic regimens. No
significant changes could be found for PlGF, FGF, and VEGF 7 days
after chemotherapy. At day 21, all growth factors returned to baseline
level. For all patients, a significant inverse correlation between SDF-
1α and CECs (Pearson R = 0.5; P < .001) and EPCs (Pearson R =
0.5; P < .001) at baseline and at 7 and 21 days was noticed. There
was a significant positive correlation between EPC and SDF-1α
4 hours after chemotherapy (Pearson R = 0.3; P < .001) but not
between CECs and SDF-1α (Pearson R = 0.09, P = .4). There
was no correlation between other cytokines and CECs or EPCs at
any time point.
Changes in CEC and EPC Levels after Chemotherapy
Associated with Response, PFS, and OS
A significant correlation was found between changes in CEC and
EPC 7 days after chemotherapy and percent tumor shrinkage accord-
ing to RECIST after three cycles of chemotherapy (Pearson R = 0.5
and 0.4, P < .01, respectively). Changes in CEC or EPC after 4 hours
and 21 days did not correlate with response to chemotherapy (Fig-
ure 2). The kinetics of the CEC 7 and 21 days after the first cycle
of chemotherapy differed significantly between patients with partial
remission/stable disease (PR/SD) and patients with progressive dis-
ease (PD) after three cycles of chemotherapy (P < .05). In patients with
PD, a large increase in CEC was seen after both 7 and 21 days (mean
increase, 386% and 1658%, respectively). In patients with PR/SD, a
mean increase in CECs of 169% was found at day 7 (P < .05) and
210% after 21 days (P < .01). EPC levels did not differ significantly
between patients with PD compared with patients with PR/SD.
Subsequently, with univariable Cox PH regression, we determined
whether CEC and EPC levels, at baseline and/or consecutive time
points after chemotherapy could predict PFS and OS. At baseline
and 4 hours after chemotherapy, no association between PFS/OS
and CEC/EPC was observed (P > .15; data not shown). Further-
more, tumor type or chemotherapy regimen could not predict PFS
Table 1. Patients’ Characteristics.
Characteristic
Sex, n (%)
Male 33 (47%)
Female 38 (53%)
Age, years
Median (range) 62 (32-82)
Tumor type, n (%)
Breast 17 (24%)
Colorectal 13 (18%)
Ovarian 8 (11%)
Esophagus 8 (11%)
Prostate 6 (9%)
Head and neck 5 (7%)
Sarcoma 4 (6%)
Cervix 4 (6%)
Other 6 (8%)
Chemotherapy regimen, n (%)
Taxane-based 23 (32%)
Anthracyclin-based 21 (30%)
5-Fluorouracil–based 11 (20%)
Platinum-based 9 (13%)
Other 4 (5%)
Response to chemotherapy after one cycle, n (%)
Partial/complete remission 21 (40%)
SD 27 (51%)
PD 5 (9%)
Follow-up, months
Median follow-up (IQR) 19 (12-28)
Median PFS (IQR) 7 (4-11)
Median OS (IQR) 14 (9-25)
IQR indicates interquartile range.
1The results from four of six patients were already published in Shaked et al. 15.
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Figure 1. Kinetics of CECs, EPCs, and growth factors during the first cycle of chemotherapy. Overall, a significant increase was seen in
CECs (A), EPCs (B), G-CSF (C), and SDF-1α (D) (n = 71, P < .01). The increase in CECs (E) and EPCs (F) seems also present in patients
treated with adjuvant chemotherapy (n = 9, P = .08 and P = .18).
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or OS in univariable analysis (P > .5; data not shown). Interestingly,
a large increase of CEC levels 7 days after chemotherapy showed a
significant association with poor PFS (P = .007) and a trend toward
poor OS (P = .09). Equally, at day 21, a large change in CEC levels
was correlated with poor PFS and OS as well (P = .002 and P = .008,
respectively). However, we focused on day 7 because this is the ear-
liest time point that could be used as predictor for PFS/OS. Tertiles
were chosen as objective cutoff points to dichotomize variables for
Kaplan-Meier analysis. For CEC levels, the 67th tertile was chosen
as cutoff to divide patients into two risk groups with distinct survival
rates. Seven days after chemotherapy, a change in CEC levels of less
than 193% (67th tertile) was associated with a significantly pro-
longed PFS (P = .01) and OS (P = .006; Figure 3, A and B, and
Table 2). In univariate analysis, EPC levels were not significantly as-
sociated with PFS or OS at days 7 and 21. However, because both
CECs and EPCs may play an important role in tumor progression,
we investigated whether combining CEC and EPC levels in one risk
model could improve the predictive accuracy. Therefore, we dichot-
omized the EPC levels at day 7 using a similar cutoff point as for
CEC (33rd tertile). After dichotomization, EPC levels at day 7 were
(borderline) significantly associated with PFS and OS (P = .046 and
P = .06, respectively; Figure 3B and Table 2). Subsequently, patients
were stratified in three risk groups with distinct survival rates based
on CEC or EPC levels above or below their cutoff point. A favor-
able group without risk factors (low CEC and low EPC levels), an
intermediate group with one risk factor (either low CEC levels or
low EPC levels) and a poor risk group with both high CEC and
high EPC levels were defined. This combination revealed an accu-
rate risk model for PFS and OS (P = .006 and P = .02, respectively).
For PFS, median survival times were 16, 11, and 5 months, respec-
tively, for the favorable, intermediate, and poor risk groups. OS was
13 months for the poor risk group. For the favorable and interme-
diate risk groups, median survival times were not reached at the end
of follow-up (Figure 3C and Table 2).
Discussion
Here, we showed that CECs and EPCs were increased in the blood
of cancer patients after treatment with various chemotherapeutic reg-
imens. This increase already started a few hours after chemotherapy
[15], but the changes after 7 and 21 days after the start of chemo-
therapy exceeded the change immediately after chemotherapy and
was not limited to specific types of chemotherapy. The increase in
CECs and EPCs is seemingly unrelated to the presence of a tumor
because adjuvant chemotherapy showed similar kinetics. This sug-
gests that EPC and CEC release after chemotherapy is part of a re-
active host response independent of tumor type and chemotherapy
regimen. This response may very well be an important factor in de-
termining the outcome of patients because EPC and CEC have been
found to stimulate tumor growth, metastasis formation, and limit
chemotherapeutic efficacy by prevention of necrosis [3,15]. Here,
we showed that the magnitude of the increase of CECs and EPCs
Figure 2. Significant correlation between the changes in CECs (A) and EPCs (B) 7 days after chemotherapy and the percent tumor
shrinkage according to RECIST. n = 53, Pearson R = 0.5 and 0.4, respectively (P < .01). CEC levels, but not EPC levels, after 7 and
21 days discriminated between patients with PD (n = 5) and SD/PR (P < .05) (C and D).
Neoplasia Vol. 12, No. 1, 2010 CEC and EPC after Chemotherapy Predict Prognosis Roodhart et al. 91
after chemotherapy was associated not only with response to chemo-
therapy after three cycles but also with PFS and OS. Although this
is the first prospective analysis of the correlation between the changes
in CECs/EPCs during the first cycle of MTD chemotherapy and
response and survival, the correlation between CECs/EPCs and prog-
nosis of patients is supported by others [21,32–34].
The chemotherapy-induced host response is likely to be mediated
by the up-regulation of various cytokines that are known to be in-
volved in progenitor cell recruitment, such as SDF-1α, VEGF, PlGF,
and G-CSF [1,2,15,18,21,35–39]. Especially SDF-1α is known for its
key role in both the release and the homing of EPC [38]. Previously,
it was shown that certain types of chemotherapy can cause an acute
Figure 3. PFS (upper panels) and OS (lower panels) of 33 patients by CECs (A) and EPCs (B) levels 7 days after chemotherapy individually and
combined into three groups (C): (1) low CEC and low EPC levels, (2) either low CEC or low EPC levels, and (3) both high CEC and EPC levels.
Table 2. Changes in CEC and EPC Levels 7 Days after Chemotherapy Associated with PFS and OS.
Cut Point Used Median PFS, months Log-rank P HR (95% CI) Median OS, months Log-rank P HR (95% CI)
CEC day 7
Lowest two tertiles* 193% 9.6 0.01 – Not reached 0.006 –
Highest tertile 4.6 2.9 (1.2-7.0) 12.7 4.5 (1.4-14.6)
EPC day 7
Lowest tertile* 30% 11.5 0.046 – Not reached 0.06 –
Highest two tertiles 6.2 2.4 (1.0-5.9) 14.6 3.8 (0.8-17.6)
EPC + CEC day 7
Favorable* Low EPC and CEC 11 0.006 – Not reached 0.02 –
Intermediate Either low EPC or low CEC 7 1.7 (0.6-4.7) Not reached 5.3 (0.6-45.1)
Poor High EPC and CEC 4 5.5 (1.7-17.4) 12.8 11.7 (1.4-98.4)
HR indicates hazard ratio.
*Risk group used as reference.
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up-regulation of SDF-1α, VEGF, and G-CSF [14,15,21,35,40]. In
addition, inhibition of SDF-1α by neutralizing antibodies could in-
hibit the release of EPC and enhanced the antitumor efficacy of the
chemotherapy [15]. We found a significant increase in SDF-1α and
G-CSF 7 days after chemotherapy. The very consistent increase in
G-CSF is not surprising given the important role in hematopoiesis
and the recovery of the bonemarrow after chemotherapy.No correlation
could be found between G-CSF and CEC or EPC. However, a sig-
nificant correlation between CEC and EPC with SDF-1α was shown,
suggestive for a role for SDF-1α in the recruitment and/or homing of
these cells. In contrast, it should be noted that plasma SDF-1α levels
already returned to baseline levels after 21 days, whereas the CECs
and EPCs continued to increase. This may suggest that other growth
factors are involved in the continued release of CECs and CEPs.
Preclinical evidence shows that antiangiogenic therapy could blunt
the release of EPCs by (chemo)therapy [14,15]. Whether this is the
case in patients is presently unclear; however, it has been shown that
metronomic chemotherapy does inhibit the release of EPCs in patients
[41]. Perhaps this inhibition of CECs and EPCs release provides an
additional explanation for the synergistic efficacy of bevacizumab
and chemotherapy. Conceptually, these findings point to an array of
new therapeutic strategies by combining chemotherapy with agents ca-
pable of inhibiting the release of progenitor cells, such as SDF-1α/
CXCR-4 antagonists, to enhance the therapeutic potential of conven-
tional chemotherapy.
A potential limitation of this study is the heterogeneous popula-
tion of chemotherapy and cancer types. However, we intended to test
whether the host bone marrow response was a specific effect or a
more generalized effect independent of the type of chemotherapy
and found evidence for the latter. Furthermore, certain types of che-
motherapy with a high response rate in certain forms of cancer could
be a confounder in the analysis. Although, in univariate analysis,
tumor type and chemotherapy regimen were both not predictive of
survival, suggesting that our results are not influenced by a specific
subgroup. There is still controversy on the definition of an EPC and
CEC. No unique identifying markers have yet been reported, and
functional characterization of the rare putative populations based on
FACS phenotypes will be difficult to realize for a large data set. Here,
we did not distinguish between viable and apoptotic CECs and EPCs.
The true biologic meaning of the cells we quantified based on the se-
lected phenotypes needs to be evaluated. However, using the selected
phenotypical definitions, the data presented here support a general role
of CECs and EPCs in the prognosis of cancer patients after chemo-
therapy and as a potential target for therapy.
In conclusion, we showed that chemotherapy evokes both an acute
and a late systemic host response composed of the release of CECs,
EPCs, growth factors, and chemokines. The extent of this release cor-
relates with the response to therapy and the prognosis of patients.
These findings provide new opportunities for further enhancing che-
motherapy efficacy by inhibition of the released factors by combina-
tion treatment. Furthermore, this study paves the way for a prospective
study in a uniformly treated patient population to determine whether
CECs and EPCs might be used as a very early predictor of response
to therapy.
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